Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Multiple Myeloma 15Waldenstrom Macroglobulinemia 1Recurrence 1Neoplasm, Residual 1Myasthenia Gravis 1Leukemia, Plasma Cell 1Infections 1Immunoglobulin Light-chain Amyloidosis 1Cytokine Release Syndrome 1

Interventions

siltuximab 4fludarabine 3Cyclophosphamide 3fludarabine phosphate 2Interleukin 1 Receptor Antagonist Protein 2AP 1903 reagent 2tocilizumab 1talquetamab 1axicabtagene ciloleucel 1Neuropsychological Tests 1Metoprolol 1Magnetic Resonance Spectroscopy 1Leukapheresis 1Infliximab 1Etanercept 1Dexamethasone 1Contrast Media 1Calcium Dobesilate 1Blood Specimen Collection 1Bendamustine Hydrochloride 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Cytokine Release Syndrome × talquetamab × Clear all
NCT05972135 2026-04-22

Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma

SCRI Development Innovations, LLC

Phase 2 Recruiting
100 enrolled
Plasma cell

Cytokine Release Syndrome, Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡